A relapsed patient with neuroblastoma, zccs373 (MYCN amplified), was identified as potentially sensitive to the BCL2 inhibitor, venetoclax, and aurora kinase A inhibitor, alisertib, by single-agent HTS (Supplementary Fig. S2) but experienced disease progression following treatment with cyclo/topo/venetoclax. The gene discussed is AURKA; the disease is neuroblastoma.